Momenta Pharmaceuticals Inc

Most Recent

  • uploads///COPAXONE
    Company & Industry Overviews

    Teva’s Copaxone Maintains Market Share amid Intense Competition

    In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.

    By Sarah Collins
  • uploads///Sandoz
    Company & Industry Overviews

    How Did Sandoz Perform in 4Q17 and Fiscal 2017?

    In 4Q17, Novartis’s (NVS) subsidiary Sandoz reported revenues of $2.6 billion.

    By Daniel Collins
  • uploads/// outlook
    Company & Industry Overviews

    A Look at Teva Pharmaceutical’s Fiscal 2018 Sales Guidance

    Teva Pharmaceutical (TEVA) provided fiscal 2018 guidance during its fiscal 2017 earnings release on February 8, 2018.

    By Sarah Collins
  • uploads///REGN revenue
    Company & Industry Overviews

    Regeneron Pharmaceuticals and Its Financial Performance

    Regeneron Pharmaceuticals (REGN) generated total revenues of $5.8 billion in fiscal 2017 compared with $4.8 billion in fiscal 2016.

    By Kenneth Smith
  • uploads///REGN RD
    Company & Industry Overviews

    A Look at Regeneron Pharmaceuticals’ Product Pipeline

    Regeneron Pharmaceuticals (REGN) currently has 15 products in clinical development.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Recent Commercial and Product Developments

    Mylan’s recent commercial developments include the acquisition of the Cold-EEZE brand from ProPhase Labs and the acquisition of Meda AB.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    The Biotechnology Industry and Multiple Sclerosis Therapies

    Most multiple sclerosis drugs are very costly at about $55,000 per year. The FDA’s April 2015 approval of a generic version of Copaxone is expected to lower the overall price of the therapy.

    By Margaret Patrick
  • uploads///Specialty
    Earnings Report

    Why Teva’s Specialty Medicines Performance Declined in 1Q15

    Teva’s new drug application for ProAir RespiClick was approved, with an expected launch of 2Q15. ProAir is the first breath-actuated dry-powder inhaler used to treat acute asthma symptoms.

    By Nicole Sario
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.